Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Mallinckrodt
Citi
Queensland Health
Merck
Argus Health
Chubb
Deloitte

Generated: August 14, 2018

DrugPatentWatch Database Preview

Chiesi Usa Inc Company Profile

« Back to Dashboard

Summary for Chiesi Usa Inc
International Patents:239
US Patents:18
Tradenames:12
Ingredients:6
NDAs:9
Patent Litigation for Chiesi Usa Inc: See patent lawsuits for Chiesi Usa Inc

Drugs and US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes 9,364,564 ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-002 Feb 21, 1992 DISCN Yes No ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes 8,658,676 ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes 8,680,052 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-003 Feb 21, 1992 5,198,226 ➤ Sign Up
Chiesi Usa Inc ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007 6,183,778 ➤ Sign Up
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 4,880,823 ➤ Sign Up
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-001 Feb 21, 1992 3,985,758 ➤ Sign Up
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 3,985,758 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CHIESI USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2.5 mg/mL, 10 mL Ampoules ➤ Subscribe 2006-12-27
➤ Subscribe Inhalation Solution 300 mg/4 mL ➤ Subscribe 2017-08-31
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 2013-06-20

Non-Orange Book US Patents for Chiesi Usa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,320,754 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
8,168,598 Optimised formulation of tobramycin for aerosolization ➤ Sign Up
8,871,736 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
9,370,586 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Sign Up
8,716,261 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Chiesi Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00722 Netherlands ➤ Sign Up PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
C0053 France ➤ Sign Up PRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: NL 37621 20120725; FIRST REGISTRATION: GB - PL 16881/0003 20111123
00520 Netherlands ➤ Sign Up PRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: RVG 104771 20111129; FIRST REGISTRATION: PL 16881/0003 20111123
209 Luxembourg ➤ Sign Up PRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
0722 Netherlands ➤ Sign Up PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Fuji
Dow
Colorcon
McKinsey
Argus Health
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.